Close to Launching Gene Therapy, Dutch Biotech Aims to Raise $100M on the NasdaqLabiotech.eu (blog)UniQure launched a public offering, perfectly timed with a rise in its stock last week after it announced a pivotal trial with a gene therapy for hemophi… Continue reading
|
Cancer Physicians Find New Hope For Patients With Gene Therapy
WOSU Public Media A new treatment for a type of childhood cancer is the first FDA-approved use of gene therapy, working as a “living drug” that can use the body’s own immune system to kill cancer cells. Researchers hope the treatment can provides an alternative for … |
|
Cancer Physicians Find New Hope For Patients With Gene Therapy
WOSU Public Media A new treatment for a type of childhood cancer is the first FDA-approved use of gene therapy, working as a “living drug” that can use the body’s own immune system to kill cancer cells. Researchers hope the treatment can provides an alternative for … |
|
New CAR–T Therapy Offers Notable Results, Potential Payer Challenges
Atlantic Information Services, Inc. 7), the agency hit another milestone with the approval of the first chimeric antigen receptor T cell (CAR-T) therapy. Novartis Pharmaceuticals Corp.’s Kymriah (tisagenlecleucel) has shown impressive results in clinical trials, but payers will face a … The FDA has just approved the revolutionary genetic modification treatmentSSL |
pharmaphorum |
Spark’s Corrective Gene Therapy Could Be First to Cost $1 Million
Atlantic Information Services, Inc. If the FDA follows an advisory committee’s lead, the agency will approve a gene therapy that treats a rare form of blindness by early next year. Spark Therapeutics Inc.’s Luxturna (voretigene neparvovec) would be the first gene therapy in the United … Out of the darkness: new gene therapies for eye diseasespharmaphorum |
|
Second CAR–T Cell Therapy Approved by FDA
JD Supra (press release) Less than two months after approving the first gene therapy for use in the U.S., that of Novartis’s Kymriah for treatment of pediatric patients with acute lymphoblastic leukemia (ALL), the FDA has approved a second single-infusion CAR–T cell therapy … |